PL1638551T3 - Związki i kompozycje immunosupresyjne - Google Patents
Związki i kompozycje immunosupresyjneInfo
- Publication number
- PL1638551T3 PL1638551T3 PL04752678T PL04752678T PL1638551T3 PL 1638551 T3 PL1638551 T3 PL 1638551T3 PL 04752678 T PL04752678 T PL 04752678T PL 04752678 T PL04752678 T PL 04752678T PL 1638551 T3 PL1638551 T3 PL 1638551T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- immunosuppressant
- immunosuppressant compounds
- diseases
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47193103P | 2003-05-19 | 2003-05-19 | |
PCT/US2004/015701 WO2004103309A2 (en) | 2003-05-19 | 2004-05-19 | Immunosuppressant compounds and compositions |
EP04752678A EP1638551B1 (en) | 2003-05-19 | 2004-05-19 | Immunosuppressant compounds and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1638551T3 true PL1638551T3 (pl) | 2012-05-31 |
Family
ID=33476902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04752678T PL1638551T3 (pl) | 2003-05-19 | 2004-05-19 | Związki i kompozycje immunosupresyjne |
Country Status (18)
Country | Link |
---|---|
US (2) | US7462629B2 (pl) |
EP (1) | EP1638551B1 (pl) |
JP (1) | JP4575920B2 (pl) |
CN (4) | CN1816544B (pl) |
AT (1) | ATE537825T1 (pl) |
AU (2) | AU2004240649A1 (pl) |
BR (1) | BRPI0410454A (pl) |
CA (1) | CA2524054C (pl) |
CY (1) | CY1112505T1 (pl) |
DK (1) | DK1638551T3 (pl) |
ES (1) | ES2379169T3 (pl) |
HK (1) | HK1090559A1 (pl) |
MX (1) | MXPA05012459A (pl) |
PL (1) | PL1638551T3 (pl) |
PT (1) | PT1638551E (pl) |
SI (1) | SI1638551T1 (pl) |
WO (1) | WO2004103309A2 (pl) |
ZA (1) | ZA200508203B (pl) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003259296A1 (en) * | 2002-07-30 | 2004-02-16 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
BRPI0413923A (pt) * | 2003-08-29 | 2006-11-07 | Ono Pharmaceutical Co | composto capaz de ligar o receptor de s1p e uso farmacêutico do mesmo |
US7638637B2 (en) * | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
AU2005217641B2 (en) * | 2004-02-24 | 2008-02-14 | Irm Llc | Immunosuppressant compounds and compositions |
TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
DE602005027074D1 (de) | 2004-07-16 | 2011-05-05 | Kyorin Seiyaku Kk | Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen |
ES2615498T3 (es) | 2004-10-12 | 2017-06-07 | Kyorin Pharmaceutical Co., Ltd. | Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol |
MX2007006706A (es) * | 2004-12-06 | 2007-10-18 | Univ Virginia | Analogos de esfingosina 1-fosfato amida de arilo. |
JP4318087B2 (ja) * | 2004-12-13 | 2009-08-19 | 小野薬品工業株式会社 | アミノカルボン酸誘導体およびその医薬用途 |
CA2595960A1 (en) * | 2005-02-08 | 2006-08-17 | Novartis Ag | Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs |
BRPI0607435A2 (pt) | 2005-02-14 | 2010-04-06 | Univ Virginia | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, e, uso de um composto |
KR20070121013A (ko) * | 2005-04-22 | 2007-12-26 | 다이이찌 산쿄 가부시키가이샤 | 헤테로 고리 화합물 |
CA2619101A1 (en) * | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
WO2007043433A1 (ja) * | 2005-10-07 | 2007-04-19 | Kyorin Pharmaceutical Co., Ltd. | 2-アミノ-1,3-プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法 |
CN101378741A (zh) * | 2006-01-27 | 2009-03-04 | 弗吉尼亚大学专利基金会 | 治疗神经性疼痛的方法 |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
AU2007212193A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
EP2053038B1 (en) | 2006-08-08 | 2016-10-05 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
ME02095B (en) | 2006-08-08 | 2014-06-30 | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient | |
EP2097371A2 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
AU2007323618A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
EP2099741A2 (en) * | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
JP5411141B2 (ja) | 2007-09-10 | 2014-02-12 | カルシメディカ,インク. | 細胞内カルシウムを調節する化合物 |
JP2011503046A (ja) * | 2007-11-08 | 2011-01-27 | ファイザー・インク | シクロブチルカルボン酸誘導体 |
GB0725104D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
JP5452237B2 (ja) | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
WO2009131090A1 (ja) * | 2008-04-21 | 2009-10-29 | 旭化成ファーマ株式会社 | アミノ酸化合物 |
GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
US9149459B2 (en) * | 2008-07-23 | 2015-10-06 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
KR20180023049A (ko) | 2008-07-23 | 2018-03-06 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
WO2010027875A2 (en) | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
CN105816453B (zh) * | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
ES2590904T3 (es) * | 2008-10-17 | 2016-11-24 | Akaal Pharma Pty Ltd | Moduladores de receptores de S1P y uso de los mismos |
EA201170828A1 (ru) * | 2008-12-18 | 2011-12-30 | Мерк Сероно С.А. | Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза |
KR20110112352A (ko) * | 2008-12-18 | 2011-10-12 | 노파르티스 아게 | 1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태 |
CN102256941A (zh) * | 2008-12-18 | 2011-11-23 | 诺瓦提斯公司 | 新的盐 |
JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス,インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
KR20120101686A (ko) * | 2009-11-24 | 2012-09-14 | 알러간, 인코포레이티드 | 치료적 유용성을 지니는 수용체 조절제로서의 신규한 화합물 |
AR079982A1 (es) * | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5,7- sustituido., composiciones farmaceuticas y procesos para prepararlos. |
AR079981A1 (es) * | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de acido carboxilico que comprenden un anillo de oxoazolopirimidina 2,5,7- sustituido |
SG182474A1 (en) * | 2010-01-14 | 2012-08-30 | Sanofi Sa | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
CN102791717B (zh) * | 2010-01-14 | 2016-03-30 | 赛诺菲 | 具有2,5-取代的噁唑并嘧啶环的羧酸衍生物 |
WO2011086081A1 (de) * | 2010-01-14 | 2011-07-21 | Sanofi-Aventis | 2,5-substituierte oxazolopyrimidinderivate |
CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
SG10201501575VA (en) | 2010-03-03 | 2015-04-29 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
CN103119038B (zh) | 2010-04-23 | 2016-05-04 | 百时美施贵宝公司 | 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1,2,4-噁二唑基-3-基)扁桃酰胺 |
JP2013525448A (ja) | 2010-04-27 | 2013-06-20 | カルシメディカ,インク. | 細胞内カルシウムを調節する化合物 |
WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
WO2012009649A1 (en) * | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
MX337711B (es) | 2010-08-27 | 2016-03-15 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
ES2548258T3 (es) | 2010-09-24 | 2015-10-15 | Bristol-Myers Squibb Company | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 |
US8492561B2 (en) * | 2010-12-03 | 2013-07-23 | Allergan, Inc. | Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators |
WO2012074780A1 (en) * | 2010-12-03 | 2012-06-07 | Allergan, Inc. | Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
CN103347510B (zh) | 2010-12-07 | 2015-11-25 | 艾米拉医药股份有限公司 | 溶血磷脂酸受体拮抗剂及其在治疗纤维化中的用途 |
TR201809293T4 (tr) | 2010-12-07 | 2018-07-23 | Amira Pharmaceuticals Inc | Polisiklik LPA1 antagonisti ve kullanımları. |
HUE031658T2 (en) * | 2011-02-07 | 2017-07-28 | Biogen Ma Inc | S1P modulating agents |
US8541587B2 (en) | 2011-04-05 | 2013-09-24 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists |
MX2013011979A (es) * | 2011-04-14 | 2014-02-06 | Allergan Inc | Derivados de metilamina biciclica de fenilo como moduladores de los receptores de la esfingosina-1 fosfato. |
US8735402B2 (en) * | 2011-07-07 | 2014-05-27 | Sanofi | Cycloalkyloxycarboxylic acid derivatives |
US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
EP2768494A1 (en) * | 2011-10-21 | 2014-08-27 | Novartis AG | Dosage regimen for an s1p receptor modulator or agonist |
CN104105687B (zh) * | 2012-02-03 | 2018-01-02 | 诺华股份有限公司 | 制备n‑(4‑环己基‑3‑三氟甲基‑苄氧基)‑乙亚氨酸乙酯的方法 |
WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CN104736524B (zh) | 2012-12-21 | 2017-06-23 | 国立研究开发法人量子科学技术研究开发机构 | 用于对脑内所蓄积的Tau蛋白质进行成像的新的化合物 |
WO2014127033A1 (en) * | 2013-02-13 | 2014-08-21 | Allergan, Inc. | Azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
EP2990055B1 (en) | 2013-04-26 | 2019-06-05 | Kyoto University | Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it |
CN103408501B (zh) * | 2013-08-14 | 2016-03-09 | 合肥医工医药有限公司 | 苄基嘧啶衍生物、其制备方法及其医药用途 |
WO2015042052A1 (en) | 2013-09-17 | 2015-03-26 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EP3046905A4 (en) | 2013-09-17 | 2017-03-22 | Pharmakea Inc. | Vinyl autotaxin inhibitor compounds |
WO2015048301A1 (en) | 2013-09-26 | 2015-04-02 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
EP3878848A1 (en) | 2013-11-22 | 2021-09-15 | Sabre Therapeutics LLC | Autotaxin inhibiting indole compounds |
PL3102576T3 (pl) | 2014-02-03 | 2019-12-31 | Vitae Pharmaceuticals, Llc | Dihydropirolopirydynowe inhibitory ror-gamma |
UA118989C2 (uk) | 2014-10-14 | 2019-04-10 | Вітае Фармасьютікалс, Інк. | Дигідропіролопіридинові інгібітори ror-гамма |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
KR20230151072A (ko) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
WO2016144703A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
JP6873919B2 (ja) | 2015-05-27 | 2021-05-19 | セイバー セラピューティクス エルエルシー | オートタキシン阻害剤とその使用 |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
US10556907B2 (en) * | 2015-08-28 | 2020-02-11 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic compounds as S1P modulators |
CN108463458B (zh) | 2015-11-20 | 2022-02-01 | 生命医药有限责任公司 | ROR-γ的调节剂 |
TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
CN109310763B (zh) * | 2016-06-10 | 2022-10-21 | Io治疗公司 | 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂 |
JP7079772B2 (ja) | 2016-09-07 | 2022-06-02 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤の結晶形態および製造方法 |
WO2018048942A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Uses of a lysyl oxidase-like 2 inhibitor |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
WO2019023207A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF RORƳ |
MX2020011959A (es) * | 2018-05-09 | 2021-02-17 | Aprinoia Therapeutics Ltd | Compuestos de heteroarilo y usos de los mismos. |
CN110776450B (zh) * | 2018-07-27 | 2022-09-27 | 广东东阳光药业有限公司 | 一种辛波莫德晶型及其制备方法 |
KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
CN113072474A (zh) * | 2018-12-06 | 2021-07-06 | 上海济煜医药科技有限公司 | 作为免疫调节剂的化合物及其制备方法和应用 |
TW202033500A (zh) * | 2018-12-06 | 2020-09-16 | 大陸商上海濟煜醫藥科技有限公司 | 作為免疫調節的芳環衍生物及其製備方法和應用 |
CN111484434A (zh) * | 2019-01-29 | 2020-08-04 | 东莞市东阳光仿制药研发有限公司 | 一种辛波莫德晶型及其制备方法 |
WO2020173346A1 (zh) * | 2019-02-25 | 2020-09-03 | 广东东阳光药业有限公司 | 一种辛波莫德的制备方法 |
CA3161455A1 (en) | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Limited | Compounds for degrading tau protein aggregates and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH540247A (de) * | 1967-04-21 | 1973-09-28 | Ciba Geigy Ag | Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen |
IL109161A0 (en) * | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
JPH10504569A (ja) * | 1994-08-24 | 1998-05-06 | イーライ・リリー・アンド・カンパニー | 向代謝性グルタメート受容体拮抗剤としてのピロリジニルジカルボン酸誘導体 |
US6110922A (en) * | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
KR20020027463A (ko) * | 1999-07-12 | 2002-04-13 | 우에노 도시오 | 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제 |
EP1424078A4 (en) * | 2001-09-04 | 2009-03-25 | Ono Pharmaceutical Co | RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT |
US20050143372A1 (en) * | 2001-10-30 | 2005-06-30 | Shomir Ghosh | Compounds, pharmaceutical compositions and methods of use therefor |
TWI246423B (en) * | 2001-12-14 | 2006-01-01 | Zentaris Gmbh | Tetrahydrocarbazole derivatives as ligands for g-protein-coupled receptors (GPCR) |
JP4430941B2 (ja) * | 2002-01-18 | 2010-03-10 | メルク エンド カムパニー インコーポレーテッド | Edg受容体作動薬 |
US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
DE10207844A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
KR100681585B1 (ko) * | 2002-04-26 | 2007-02-09 | 에프. 호프만-라 로슈 아게 | 아이소퀴놀린 유도체 |
JP2007186422A (ja) * | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
-
2004
- 2004-05-19 CN CN2004800188602A patent/CN1816544B/zh not_active Expired - Fee Related
- 2004-05-19 CN CN2004800131943A patent/CN1787817B/zh not_active Expired - Fee Related
- 2004-05-19 BR BRPI0410454-4A patent/BRPI0410454A/pt not_active IP Right Cessation
- 2004-05-19 AU AU2004240649A patent/AU2004240649A1/en not_active Abandoned
- 2004-05-19 US US10/849,450 patent/US7462629B2/en not_active Expired - Fee Related
- 2004-05-19 JP JP2006533219A patent/JP4575920B2/ja not_active Expired - Fee Related
- 2004-05-19 PL PL04752678T patent/PL1638551T3/pl unknown
- 2004-05-19 SI SI200431832T patent/SI1638551T1/sl unknown
- 2004-05-19 CN CN2004800139502A patent/CN1791592B/zh not_active Expired - Fee Related
- 2004-05-19 EP EP04752678A patent/EP1638551B1/en not_active Not-in-force
- 2004-05-19 CN CN2004800132486A patent/CN1791395B/zh active Active
- 2004-05-19 PT PT04752678T patent/PT1638551E/pt unknown
- 2004-05-19 MX MXPA05012459A patent/MXPA05012459A/es active IP Right Grant
- 2004-05-19 US US10/849,079 patent/US7060697B2/en not_active Expired - Fee Related
- 2004-05-19 DK DK04752678.5T patent/DK1638551T3/da active
- 2004-05-19 WO PCT/US2004/015701 patent/WO2004103309A2/en active Application Filing
- 2004-05-19 ES ES04752678T patent/ES2379169T3/es active Active
- 2004-05-19 CA CA2524054A patent/CA2524054C/en not_active Expired - Fee Related
- 2004-05-19 AT AT04752678T patent/ATE537825T1/de active
-
2005
- 2005-10-11 ZA ZA200508203A patent/ZA200508203B/en unknown
-
2006
- 2006-10-17 HK HK06111346.2A patent/HK1090559A1/xx not_active IP Right Cessation
-
2008
- 2008-07-11 AU AU2008203088A patent/AU2008203088A1/en not_active Abandoned
-
2012
- 2012-03-16 CY CY20121100286T patent/CY1112505T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0410454A (pt) | 2006-06-13 |
CN1791395B (zh) | 2012-09-26 |
EP1638551A4 (en) | 2008-12-31 |
CN1787817B (zh) | 2011-09-07 |
DK1638551T3 (da) | 2012-04-02 |
CN1816544A (zh) | 2006-08-09 |
US20050009786A1 (en) | 2005-01-13 |
CA2524054A1 (en) | 2004-12-02 |
CN1816544B (zh) | 2011-06-08 |
ES2379169T3 (es) | 2012-04-23 |
ZA200508203B (en) | 2007-02-28 |
US20050014724A1 (en) | 2005-01-20 |
CN1791592B (zh) | 2012-07-04 |
WO2004103309A3 (en) | 2005-03-03 |
JP2006528987A (ja) | 2006-12-28 |
CY1112505T1 (el) | 2015-12-09 |
US7462629B2 (en) | 2008-12-09 |
MXPA05012459A (es) | 2006-02-22 |
PT1638551E (pt) | 2012-03-28 |
WO2004103309A2 (en) | 2004-12-02 |
CA2524054C (en) | 2012-04-24 |
CN1791395A (zh) | 2006-06-21 |
ATE537825T1 (de) | 2012-01-15 |
EP1638551B1 (en) | 2011-12-21 |
SI1638551T1 (sl) | 2012-04-30 |
US7060697B2 (en) | 2006-06-13 |
AU2008203088A1 (en) | 2008-08-07 |
CN1787817A (zh) | 2006-06-14 |
AU2004240649A1 (en) | 2004-12-02 |
HK1090559A1 (en) | 2006-12-29 |
EP1638551A2 (en) | 2006-03-29 |
JP4575920B2 (ja) | 2010-11-04 |
CN1791592A (zh) | 2006-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1090559A1 (en) | Immunosuppressant compounds and compositions | |
TNSN05294A1 (en) | Immunosuppressant compounds and compositions | |
TW200505442A (en) | Immunosuppressant compounds and compositions | |
WO2004113330A8 (en) | Immunosuppressant compounds and compositions | |
WO2005082089A3 (en) | Immunosuppressant compounds and compositions | |
WO2004071442A3 (en) | Novel bicyclic compounds and compositions | |
TW200612892A (en) | Novel compounds | |
TW200505837A (en) | Novel compounds | |
TW200519075A (en) | Novel compounds | |
IL190654A (en) | Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them | |
TW200716120A (en) | Pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
TW200635903A (en) | Therapeutic agents | |
TW200504034A (en) | Therapeutic agents | |
GB0313612D0 (en) | Organic compounds | |
TW200633986A (en) | Therapeutic agents | |
TW200720260A (en) | Prokineticin 1 receptor antagonists | |
TW200716566A (en) | Prokineticin 2 receptor antagonists | |
MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
TW200514781A (en) | Novel compounds | |
GB0420831D0 (en) | Novel compounds | |
TW200734324A (en) | Therapeutic agents | |
TW200801005A (en) | Acetylenic piperazines as metabotropic glutamate receptor antagonists | |
TW200517382A (en) | Imidazole derivatives | |
MX2007010841A (es) | 8-pirrolidinobenzimidazoles biciclicos sustituidos, un metodo para su produccion y su uso como medicamentos. |